Senseonics reports Q4 EPS 2c vs 19c last year

Reports Q4 revenue $5.6M, consensus $5.42M. "2022 was a year of notable progress in building the Eversense business, with FDA approval, CE mark and global launch of the E3 system and the acceleration of a pivotal trial for a 365-day sensor configuration that we plan will also support both ICGM and a pediatric indication," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "Together with establishing the Nurse Practitioner Group partnership, expanding E3 coverage from Medicare and commercial payers, and coordinating expansion of the Ascensia U.S. salesforce, we have further advanced important initiatives to help bring the benefits of Eversense long-term implantable CGM to growing numbers of patients."